DOCSLIB.ORG

Pharmacology of Autonomic Nervous System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacology of Autonomic Nervous System Yerevan State Medical University after Mkhitar Heratsi M.G. Balasanyan, L.G. Dheryan, A.V. Baykov, A.G. Tananyan, N.A. Voskanyan Pharmacology Guideline For the third year students Pharmacology of autonomic nervous system Yerevan-2017-2018 Pharmacology of autonomic nervous system Nervous system is divided into 2 parts: Central nervous system (CNS) and peripheral nervous system (PNS). CNS in its` term consists of brain and spinal cord. PNS consists of all afferent (sensory) neurons, which provide impulse conduction from peripheral organs and all efferent (motor) neurons, which provide impulse conduction from center to periphery. Efferent part of nervous system includes 2 main parts: autonomic nervous system and somatic nervous system. Vegetative or autonomic nervous system acts out of human’s will and isn`t directly regulated by the human`s conscious. VNS maintains body homeostasis and regulates function of inner organs (digestion, blood supply of organs, regulation of blood pressure etc.). Synapses of SNS are localized in CNS, but peripheral synapses of VNS are localized out of CNS in ganglions. Preganglionic nerves of VNS are myelinated, postganglionic nerves are not myelinated. VNS innervates smooth muscles, myocardium and exocrine glands. Besides VNS is included also peripheral ganglions. The mediators of VNS are NA and ACH. Somatic nervous system (SNS) is regulated by conscious and regulates motor activity, breathing, position. SNS innervates skeletal muscles, synapses are located in CNS, nerve fibers are myelinated. SNS doesn`t have ganglions, the mediator of efferent ways is ACH (picture and table 1). 3 Picture 1. General description of somatic and autonomic nervous system Table 1: comparative properties of SNS and VNS Somatic Vegetative 1 Innervated organs Skeletal muscles All other organs 2 Localization of peripheral Mainly inside of Out of CNS /in synapses CNS ganglions/ 3 Neurons Myelinated Preganglionic are mielinated, postganglionic are non- mielinated 4 Existance of peripheral absent Exists ganglions 5 Efferent neurotransmitter acetylcholine Acetylcholine Noradrenaline According to neurotransmitter which is released from synapses VNS is divided into sympathetic /mediator is noradrenaline/ and parasympathetic nervous systems /mediator is acetylcholine/: These 2 systems have afferent, central and efferent parts. Afferent way of VNS. The majority of nerves are mixed and include nonmyelinated afferent nerve fibers. Their neurons are located in 4 ganglions of dorsal roots of spinal nerves and in sensory ganglions of cerebral nerves. These ways are conducting pain, cardio-vascular, respiratory and other inner reflexes. VNS Central centers. Are located in hypothalamus. Their dorsal and lateral nuclei are symphatic, anterior and intermediate are parasymphatic. Parasymphatic central neurons have cranio-sacral location. Picture 2. The general description of location of sympathetic and parasympathetic nervous systems: Efferent way of VNS Majority of organs receive both sympathetic and parasympathetic innervations, which are functionally controversial. Some inner organs receive only sympathetic or parasympathetic innervations. For example, majority of blood vessels, spleen, sweat glands and piloerectile muscles receive mainly sympathetic innervations, but cilliary muscle, glands system of stomach and pancreas receive mainly parasympathetic innervations. 5 Efferent way of VNS consists of two neurons: preganglionic and postganglionic. Bodies of preganglionic neurons of parasympathetic nervous system have craniosacral localization. Craniosacral nuclei are localized in midbrain and medulla. In this case cholinergic neuronal endings are going through the following craniocerebral neurons: lll /n.oculomotorius/, Vll /n.facialis/, lX /n. glossopharyngeus/, X /n.vagus/. Bodies of preganglionic neurons in sacral part of spinal cord are localized in lateral horns of grey substance (picture 2). Bodies of preganglionic nerves of sympathetic nervous system are localized mainly in thoracolumbal part of spinal cord in lateral horns: C8, Th1–L3. Preganglionic axons of both sympathetic and parasympathetic neurons are interrupted in vegetative ganglia, where with ganglionar neurons they form synaptic contact. Postganglionic neurons are started from these ganglions, which innervate the organ. Sympathetic preganglionic nerves are short and their ganglions are localized far from organ in paravertebral column. Postganglionic nerves are longer (Picture 2). Parasympathetic preganglionic nerves are longer and most of them are interrupted in ganglions which are localized near organs or inside of organs. Parasympathetic postganglionar nerves are short. Mediator in all vegetative ganglions is acetylcholine, so both sympathetic and parasympathetic preganglionic nerves are cholinergic, but sympathetic postganglionic nerves are adrenergic, parasympathetic postganglionic nerves are cholinergic. 6 As it was mentioned above, efferent way of VNS consists of 2 neurons. There are some exceptions, for instance, efferent neurons which innervate adrenal medulla. The chromaphinic cells of adrenal medulla are close to neurons of sympathetic ganglions, so only preganglionic /cholinergic/ neurons are involved in innervation of adrenal medulla, where mediator is acetylcholine. So, here we have only one way, which consists of one neuron only and stimulation of this neurons causes release of adrenaline (Table 2). Thus, motor, vegetative preganglionar and parasympathetic postganglionar nerves are cholinergic, but sympathetic postganglionar nerves are adrenergic. Table 2. Comparative properties of Parasympathetic /PNS/ and Sympathetic /SNS/ nervous systems SNS PNS 1 Central part thoracolumbal craniosacral /Th1-L2 or L3/ part /involved in III, of spinal cord VII, IX, X, S2-S4 neurons/ 2 Localization of ganglions Out of organs Near organs or inside of organs 3 Length of postganglionar long Short neurons 4 Neurotransmitter Noradrenaline Acetylcholine /mediator/ acetylcholine 5 Main function Mobilization of Accumulation of strength and energy, digestion defense of organism in stress and emergency situation 7 Intestinal neuronal system /INS/ complex of different neurons, which is localized in walls of GIT. Some authors consider INS as the third part of VNS. It consists of muscular plexus /Auerbach plexus/, submucous plexus /Plexus of Mejsnier/ and sensitive – endings of afferent neurons. This system receives preganglionic neurons from PNS and postganglionic axons of SNS. Neurons which begin from this plexus reach the mucous membrane of intestines and regulate motor activity of intestines and secretor activity of cells. INS of VNS has only modulating activity, because here there are a lot of neuromediators and neuroregulating substances: NO, neuropeptides, substance P, serotonine etc.) Structure of synapse of autonomic nervous system Synapse consists of 1. Presynaptic membrane, from where, in response to impulse /action potential/, is taking place release of mediator, which is synthesized in axonal endings and is accumulated in vesicles. 2. Postsynaptic membrane, where mediator is recognized and the appropriate response is formed. 3. Synaptic cleft, which is the space of 20-40nm between presynaptic and postsynaptic membranes. It is polysaccharidal jelly with many tubules where mediator is diffused. 4. Connetive tissue filaments, which limits synapses and prevent diffusion of mediator to systemic blood flow (picture 3). 8 Picture 3. Structure of synapse Main stages of neurotransmission 1. Synthesis and accumulation of mediator 2. Impulse transmission and release of mediator 3. Interaction of mediator with pre- and postsynaptic membrane receptors 4. Formation of postsynaptic activity 5. Mediator effect elimination 1. Synthesis and accumulation of mediator Synthesis of non-peptide mediators takes place in axonal endings and synthetized mediator is accumulated in special synaptic vesicles. Mediators with peptide properties are synthesized in neuronal bodies then go to the axonal endings are accumulated in vesicles, where they are 9 transformed into main mediators. Transport of mediators or premediators into vesicles are perfomed by means of proton pump. At rest only small quantity of mediator is released into synaptic cleft and they form tiny postsynaptic potential /0,1-3mV/. This process provides physiological reactivity of effector organ. Synaptic vesicles are localized and accumulated near presynaptic membrane in special part which is called «active zone» (picture 4). 2. Impulse transmission and release of mediator. Permeability of axonal membrane for K+ and H+ ions at rest is very high, and the quantity of K+ and H+ ions inside of cell is very high, but in outside of cell Na+ and Cl- are in large quantity. As a result the inner surface of cell membrane has negative charge compare to upper surface of membrane. Depolarization of axonal ending brings to opening of potential dependent Na+–channels and influx of Na+-ions which cause change of charge. This is the first stage of depolarization. On the second stage of depolarization inactivation of potential dependent Na+–channels and opening of K+-channels takes place which brings to limitation of depolarization and repolarization of presynaptic membrane. Ionic ratio comes back to initial level in refractory period due to activity of Na+ / K+ – ATPase. Increase of level of Na+ and mainly Ca2+-ions in presynaptic part result in interaction between proteins of synaptic vesicles /synaptotagmine, synaptobrevin /VAMP-vesicle-associated
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/401 (2006.01) A61P 9/12 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/405 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/7048 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US20 13/039904 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 May 2013 (07.05.2013) NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (26) Publication Language: English ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/644,134 8 May 2012 (08.05.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (72) Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicants : STEIN, Emily A.
    [Show full text]
  • Evaluation and Management of Bradydysrhythmias
    VISIT US AT BOOTH # 116 AT THE ACEP SCIENTIFIC ASSEMBLY IN SEATTLE, OCTOBER 14-16, 2013 September 2013 Evaluation And Management Volume 15, Number 9 Of Bradydysrhythmias In The Author Nathan Deal, MD Assistant Professor, Section of Emergency Medicine, Baylor Emergency Department College of Medicine, Houston, TX Peer Reviewers Abstract Joshua M. Kosowsky, MD Vice Chair for Clinical Affairs, Department of Emergency Medicine, Brigham and Women’s Hospital; Assistant Professor, Bradydysrhythmias represent a collection of cardiac conduction Harvard Medical School, Boston, MA abnormalities that span the spectrum of emergency presentations, Charles V. Pollack, Jr., MA, MD, FACEP Professor and Chair, Department of Emergency Medicine, from relatively benign conditions to conditions that represent Pennsylvania Hospital, Perelman School of Medicine, University serious, life-threatening emergencies. This review presents the of Pennsylvania, Philadelphia, PA electrocardiographic findings seen in common bradydysrhythmias CME Objectives and emphasizes prompt recognition of these patterns. Underlying Upon completion of this article, you should be able to: etiologies that may accompany these conduction abnormalities are 1. Recognize the electrocardiographic features of common discussed, including bradydysrhythmias that are reflex mediated bradydysrhythmias. (including trauma induced) and those with metabolic, environ- 2. Consider a variety of pathologies that give rise to mental, infectious, and toxicologic causes. Evidence regarding the bradydysrhythmias. 3. Identify the emergent therapies for the unstable patient management of bradydysrhythmias in the emergency department with bradycardia. is limited; however, there are data to guide the approach to the un- 4. Be familiar with common antidotes for acute toxicities that stable bradycardic patient. When decreased end-organ perfusion is result in bradydysrhythmias.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Intérêts Et Limites De La Bile Et De L'humeur Vitrée Comme Matrices Alternatives En Toxicologie Médicolégale
    Intérêts et limites de la bile et de l’humeur vitrée comme matrices alternatives en toxicologie médicolégale. Fabien Bévalot To cite this version: Fabien Bévalot. Intérêts et limites de la bile et de l’humeur vitrée comme matrices alternatives en toxicologie médicolégale.. Toxicologie. Université Claude Bernard - Lyon I, 2014. Français. NNT : 2014LYO10362. tel-01167119 HAL Id: tel-01167119 https://tel.archives-ouvertes.fr/tel-01167119 Submitted on 23 Jun 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Année 2014 THESE DE L'UNIVERSITE DE LYON Délivrée par L'UNIVERSITE CLAUDE BERNARD LYON 1 ECOLE DOCTORALE INTERDISCIPLINAIRE SCIENCES-SANTE (E.D.I.S.S.) DIPLOME DE DOCTORAT (arrêté du 7 aout 2006) Soutenue publiquement le 17 décembre 2014 Par M BÉVALOT Fabien INTERETS ET LIMITES DE LA BILE ET DE L'HUMEUR VITREE COMME MATRICES ALTERNATIVES EN TOXICOLOGIE MEDICOLEGALE Directeurs de Thèse : Pr. GUITTON Jérôme Pr. FANTON Laurent JURY: Pr. Michel Tod (Président du Jury) Pr. Marc Augsburger (Rapporteur) Dr. Pascal Kintz (Rapporteur) Dr. Hélène Eysseric (Examinatrice) Pr. Laurent Fanton (Directeur de Thèse) Pr. Jérôme Guitton (Directeur de Thèse) UNIVERSITE CLAUDE BERNARD - LYON 1 Président de l’Université M.
    [Show full text]
  • DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection
    DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Committee. INSTITUTION National Heart, Lung, and Blood Inst. (DHHS/NIH), Bethesda, MD. PUB DATE 88 NOTE 64p. PUB TYPE Guides - Non-Classroom Use (055) EDRS PRICE MF01/PC03 Plus Postage. DESCRIPTORS *Cardiovascular System; Clinical Diagnosis; *Drug Therapy; *Hypertension; *Pharmacology; Physical Examinations; Physical Health; *Physical Therapy ABSTRACT The availability of an increased variety of therapeutic approaches provides the opportunitl to improve hypertension control while minimizing adverse effects that may influence cardiovascular complications and adherence to therapy. This report serves two purposes: (1) to guide practicing physicians and other health professionals in their care of hypertensive patients; and (2) to guide health professionals participating in the many community high blood pressure control programs. Contents include: (1) definition and prevalence of high blood pressure; (2) detection, confirmation and referral; (3) evaluation and diagnosis; (4) treatment--nonpharmacologic and pharmacologic therapy, and long-term maintenance of therapy; (5) considerations in individual therapy; and (6) special populations and management problems. Fifty-five references are included. (JD) *********************************************************************** Reproductions supplied by EDRS are the best that can be made from the original document. ************************************-*********************************
    [Show full text]
  • Initial Medication Selection for Treatment of Hypertension in an Open-Panel HMO
    J Am Board Fam Pract: first published as 10.3122/jabfm.8.1.1 on 1 January 1995. Downloaded from Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past 25 years recommendations for treating hypertension have evolved from a stepped-care approach to monotherapy or sequential monotherapy as experience has been gained and new antihypertensive agents have been introduced. In an effort to develop a disease management strategy for hypertension, we investigated the prescribing patterns of initial medication therapy for newly treated hypertensive patients. Methods: We examined paid claims data of an open-panel HMO located in the midwest. Charts from 377 patients with newly treated hypertension from a group of 12,242 hypertenSive patients in a health insurance population of 85,066 persons were studied. The type of medication regimen received by patients newly treated for hypertension during an 18-month period was categorized into monotherapy, sequential monotherapy, stepped care, and initial treatment with multiple agents. With monotherapy, the class of medication was also reported. Associations between use of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or (3-blockers and presence of comorbid conditions were reported. Results: Fifty-five percent of patients received monotherapy, 22 percent received stepped care, and 18 percent received sequential monotherapy. Of those 208 patients receiving monotherapy, 30 percent were prescribed a calcium channel blocker, 22 percent an ACE inhibitor, and 14 percent a f3-blocker. No customization of treatment for comorbid conditions was noted.
    [Show full text]
  • Cardiovascular Responses to Hypoxemia in Sinoaortic-Denervated Fetal Sheep
    003 1-399819 1 /3004-038 1$03.0010 PEDIATRIC RESEARCH Vol. 30. No. 4, I991 Copyright ID1991 International Pediatric Research Foundation. Inc. I1riiirc~c/it1 U.S. ,.I Cardiovascular Responses to Hypoxemia in Sinoaortic-Denervated Fetal Sheep JOSEPH ITSKOVITZ (ELDOR), EDMOND F. LAGAMMA. JAMES BRISTOW, AND ABRAHAM M. RUDOLPH Ccirdiovascz~karResearch Instillrle. Unlver:c.i/yqf Califi~rniu,Sari Francisco. Sun Francisco. Cu11fi)rilia94/43 ABSTRACT. Fetal cardiovascular response to acute hy- hypoxemia in postnatal life (1 3). The vascular effects of periph- poxemia is characterized by bradycardia, hypertension, and eral chemoreceptor stimulation, with ventilation held constant, redistribution of cardiac output. The role of aortic and include coronary vasodilation and vasoconstriction in the carotid chemoreceptors in mediating these responses was splanchnic organs and the skeletal muscles. Stimulation of the examined in eight sinoaortic-denervated and nine sham- carotid body chemoreceptors results in reflex bradycardia and operated fetal lambs. Blood gases, pH, heart rate, arterial negative inotropic responses. The bradycardia and peripheral pressure, and blood flow distribution were determined be- vasoconstriction during carotid chemoreceptor stimulation can fore and during hypoxemia. In intact fetuses, heart rate be reversed by effects arising from concurrent hypernea (13). fell from 184 -+ 12 to 165 + 23 beatslmin (p< 0.01) but The arterial chemoreceptors (aortic and carotid bodies) are increased from 184 + 22 to 200 + 16 beatslmin (p< 0.05) active in the fetal lamb and are responsive to hypoxemia (14- in the sinoaortic-denervated fetuses. Intact fetuses showed 21). Stimulation of the fetal arterial chemoreceptors result in an early hypertensive response to hypoxemia, whereas the bradycardia, which is abolished by SAD (19, 20, 22).
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Investigation of the Cardiovascular Action of Sympathetic Amines Using Two Kinds of Strain Gauge Instrument
    Nagoya ]. med. Sci. 29: 155-165, 1966. INVESTIGATION OF THE CARDIOVASCULAR ACTION OF SYMPATHETIC AMINES USING TWO KINDS OF STRAIN GAUGE INSTRUMENT ATSUSHI SEKIYA, MITSUYOSHI NAKASHIMA, AND ZENGO KANDA Department of Pharmcology, Nagoya University School of Medicine (Director: Prof. Zen go Kanda) SUMMARY Ventricular responses of a few catecholamines in rabbits were studied with the use of various parameters: blood pressure, systemic output or stroke volume, heart rate, ventricular contractile force and change of segment length of ventricular muscle. In recording ventricular contraction, two kinds of apparatus, strain gauge compass and arch, which we devised, were used. Simultaneous recordings of these various factors permit characterization and direct comparison of the nature and sequence of left ventricular responses by infusion of catecholamines. Epinephrine or norepinephrine, in smaller dose produced almost the same changes in ventricular contractile force and segment length of ventricular muscle. However, in the course of a short time after the administration of the large dose of these drugs, the change of coutractile force by means of strain gauge arch was significant, but the change of muscle segment length measused by means of strain gauge compass was more complicated and gave us much information of cardiac function. Namely, there were a decrease of stroke deflection with a decrease of stroke volume and a downward displacement of systolic and diastolic excursion curve which meant heart dilatation. By the administration of methoxamine, the changes of muscle segment length were more marked than the changes of contractile force. By the administration of isoproterenol, the changes of contractile force were more marked than the changes of muscle segment length changes.
    [Show full text]